Meriofert Spuit

Human Menopausal Gonadotropin, the active ingredient in Meriofert Spuit, is a gonadotropin presented as an injectable solution for intramuscular or subcutaneous use. It stimulates ovarian follicular development and ovulation in women with anovulation or hypogonadotropic hypogonadism. GNH USA supplies Meriofert Spuit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meriofert Spuit is a gonadotropin used in reproductive‑hormone pathways to promote follicular growth and ovulation. - Induction of ovulation in women with anovulation: restores natural ovulatory cycles to enable conception. - Controlled ovarian stimulation for assisted reproductive technologies: enhances follicle recruitment for IVF or ICSI procedures. - Treatment of hypogonadotropic hypogonadism: replaces deficient LH and FSH to support normal ovarian function.

Adverse reactions may occur with any injectable reproductive hormone therapy.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the administration site. - Abdominal bloating or discomfort: transient gastrointestinal symptoms. - Headache: mild to moderate intensity. - Nausea: occasional upset stomach. - Mild ovarian cyst formation: small, self‑limiting cysts.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (OHSS): severe fluid shift and abdominal distension. - Multiple pregnancy: higher-order gestations requiring specialized care. - Thromboembolic events: rare clot formation in veins. - Severe allergic reaction: anaphylaxis with rash, swelling, or breathing difficulty. - Ovarian torsion: acute pelvic pain due to twisted ovary.

Use Meriofert Spuit only under specialist supervision with appropriate monitoring. - Baseline assessment: evaluate ovarian reserve and hormonal profile before initiating therapy. - Monitor estradiol: frequent serum estradiol measurements to detect excessive response. - Avoid in pregnancy: contraindicated in confirmed pregnancy; ensure effective contraception. - Caution with ovarian cysts: assess for existing cysts prior to treatment. - Screen for hormone‑sensitive tumors: avoid use in patients with active estrogen‑dependent cancers. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Drug interactions may modify the efficacy or safety of Meriofert Spuit.

Major Interactions (Avoid): - Concurrent use of other gonadotropins: may cause excessive ovarian stimulation. - High‑dose estrogen therapy: can blunt the intended ovarian response.

Moderate Interactions (Monitor Closely): - GnRH agonists or antagonists: may require dose adjustment of hMG. - Anticoagulants: monitor for increased bleeding risk at injection sites. - Corticosteroids: may alter hormonal metabolism and require observation.